Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Return on Capital Employed came in at 67.38% in Q1 2026, down 1590.0% YoY from 4.52% in Q1 2025, and up 10.55% on a QoQ basis from 75.33% in Q4 2025.
Barinthus Biotherapeutics (BRNS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Return on Capital Employed data on file, last reported at 67.38% in Q1 2026.
- Quarterly Return on Capital Employed fell 1590.0% year-over-year to 67.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 67.38% (down 1590.0% YoY) and the FY2025 annual result came in at 59.18%, down 1960.0% from the prior year.
- Return on Capital Employed grew to 67.38% in Q1 2026, from 75.33% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1.67% in Q3 2022 to a low of 75.87% in Q3 2025.
- A 5-year average of 36.99% and a median of 40.16% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 1684 bps — and 2023, when it sank 4223 bps.
- Tracing BRNS's Return on Capital Employed over 5 years: stood at 1.52% in 2022, then sank by 2529 bps to 40.03% in 2023, then fell by 7 bps to 42.79% in 2024, then slumped by 76 bps to 75.33% in 2025, then climbed by 11 bps to 67.38% in 2026.
- The last three Return on Capital Employed figures came in at 67.38% (Q1 2026), 75.33% (Q4 2025), and 75.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | -57.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.84% |
| Mar 31, 2026 | -67.38% |
| Dec 31, 2025 | -75.33% |
| Sep 30, 2025 | -75.87% |
| Jun 30, 2025 | -62.33% |
| Mar 31, 2025 | -51.48% |
| Dec 31, 2024 | -42.79% |
| Sep 30, 2024 | -37.40% |
| Jun 30, 2024 | -40.16% |
| Mar 31, 2024 | -40.87% |
| Dec 31, 2023 | -40.03% |
| Sep 30, 2023 | -40.56% |
| Jun 30, 2023 | -27.16% |
| Mar 31, 2023 | -10.28% |
| Dec 31, 2022 | -1.52% |
| Sep 30, 2022 | 1.67% |
| Jun 30, 2022 | -3.04% |
| Mar 31, 2022 | -14.38% |
| Dec 31, 2021 | -17.56% |
| Sep 30, 2021 | -15.16% |